IN8BIO INC. DL-,0001 Aktie

Alan S. Roemer has resigned as a director and as a member of the audit and compensation committee effective Saturday; the resignation was not due to disagreements with the company. The board appointed Jeremy Graff as interim chair. IN8bio secured up to $40.2 million in a private placement (first tranche about $20.1 million, additional $20.1 million tied to milestones for INB-619) and promoted Dr. Kate Rochlin to president and chief operating officer; the board reports no reportable related‑party transactions. » More on de.investing.com

IN8bio entered a securities purchase agreement with institutional and accredited investors to raise up to $40.2 million, split into two tranches of roughly $20.1 million each, with the second tranche tied to milestones for candidate INB-619. Shares and prepaid warrants will be sold at market price; Coastlands Capital is leading the round and H.C. Wainwright is the placement agent. The proceeds are intended to finance IND-enabling studies for INB-619 and regulatory support for INB-200/400, extending the cash runway into the first half of 2027. Separately, Ohio State University is expanding a Phase 1 study for INB-100; Mizuho lowered its price target for IN8bio from $6.00 to $4.00 but kept an Outperform rating. » More on de.investing.com

IN8bio has once again met the Nasdaq's minimum bid price requirement after its stock had previously lost significant value. The biotechnology company also reports positive results from clinical trials for glioblastoma and systemic lupus erythematosus. CEO William Ho highlights the potential for safer and more effective therapies, while the company is exploring partnerships to expand its pipeline. » More on de.investing.com